Why is Transgene Biotek falling/rising?

As of 30-Jun, Transgene Biotek Ltd's stock price is currently at 4.60, reflecting an increase of 0.18 or 4.07%. The stock has shown a strong performance today, outperforming its sector by 4.52%. Additionally, over the past week, the stock has risen by 6.98%, and over the past month, it has increased by 9.00%. However, despite these short-term gains, the stock has experienced significant declines year-to-date and over the past year, with losses of 32.65% and 47.43%, respectively. The stock's moving averages indicate that it is performing better than the 5-day, 20-day, 50-day, and 100-day averages, but it remains below the 200-day moving average. There is a noted decline in investor participation, with delivery volume falling by 34.45% against the 5-day average, which may indicate a lack of sustained interest in the stock.
In the broader market context, Transgene Biotek's recent performance contrasts with the benchmark Sensex, which has gained 2.09% over the past week and 2.65% over the past month. While the stock has outperformed the benchmark in the short term, its year-to-date performance is significantly lagging behind the Sensex, which has risen by 7.00% during the same period. This disparity highlights the challenges faced by Transgene Biotek in maintaining investor confidence despite recent price increases, as indicated by the falling delivery volumes and overall negative performance over longer time frames.